These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18425290)

  • 1. Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
    Fabrício Vde C; Amado F; Del Giglio A
    Sao Paulo Med J; 2008 Jan; 126(1):63-6. PubMed ID: 18425290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Wright JE; Norris CM; Busse PM; Lucarini JW; Fallon BG; Casey D; Andersen JW; Klein R
    Ann Intern Med; 1990 Feb; 112(3):167-72. PubMed ID: 2297193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
    Polee MB; Kok TC; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
    Anticancer Drugs; 2001 Jul; 12(6):513-7. PubMed ID: 11459997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
    Watanabe A; Taniguchi M; Sasaki S
    Anticancer Drugs; 2003 Nov; 14(10):801-7. PubMed ID: 14597874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
    Mauer AM; Kraut EH; Krauss SA; Ansari RH; Kasza K; Szeto L; Vokes EE
    Ann Oncol; 2005 Aug; 16(8):1320-5. PubMed ID: 15919687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
    Fountzilas G; Tolis C; Kalogera-Fountzila A; Misailidou D; Tsekeris P; Karina M; Nikolaou A; Samantas E; Makatsoris T; Athanassiou E; Skarlos D; Bamias A; Zamboglou N; Economopoulos T; Karanastassi S; Pavlidis N; Daniilidis J
    Med Oncol; 2005; 22(3):269-79. PubMed ID: 16110138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
    Chang PM; Teng HW; Chen PM; Chang SY; Chu PY; Tsai TL; Tai SK; Wang YF; Huang JL; Yang MH
    J Chin Med Assoc; 2008 Jul; 71(7):336-41. PubMed ID: 18653395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
    Meirovitz A; Bergerson S; Hirshoren N; Weinberger JM; Bersudski E; Daniel S; Sheva K; Perez CA
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1479. PubMed ID: 34184405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
    Colevas AD; Norris CM; Tishler RB; Lamb CC; Fried MP; Goguen LA; Gopal HV; Costello R; Read R; Adak S; Posner MR
    Am J Clin Oncol; 2002 Apr; 25(2):153-9. PubMed ID: 11943893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
    Wang J; Chang J; Yu H; Wu X; Wang H; Li W; Ji D; Peng W
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):905-11. PubMed ID: 23370661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.